Explore Latest News .

Find all the latest news on Paul Peter Tak, as well as a comprehensive list of his past interviews and features. Paul Peter’s work in immunology and the pharmaceutical industry has led him to be featured in both business and medicine specific publications.

During his time at GlaxoSmithKline, Paul Peter gave a number of interviews and briefs, including one with the Biochemical Society in 2017. In this insightful interview, Paul Peter outlined what the GSK Immunology Network was and its impact on this important area of research.

In December 2020, Paul Peter Tak spoke with Eleanor Malone, from Scrip, about the work Candel Therapeutics was undertaking in the field of cancer immunotherapy and the companies ambitious future. Paul Peter has also had more broad discussions around his career and what inspires him, such as his interview with Stephanie Sutton for The Medicine Maker, in 2020.   

Podcast People & Pioneers: Leadership and the paradigm shift in biotechnology

Leadership and the Paradigm Shift in Biotechnology: Insights from Paul Peter Tak, PhD, FMedSci, Professor, President, CEO & Board Director of Candel Therapeutics – People and Pioneers – The Podc…

The Future of Immunotherapy: An Interview with Dr. Tak

The BioHub – The Avetix Podcast – Episode 5 – Paul Peter Tak

The BioHub – The Avetix Podcast – Episode 5 – Paul Peter Tak (

Empowered Patient Podcast: Using oncolytic viral immunotherapy to kill solid tumors with Dr. Paul Peter Tak

Paul Peter Tak – Top podcast episodes (

Controlling Time: The Secret To Manufacturing

Controlling Time The Secret To Manufacturing (

Ignition of a new era of cancer treatments

Candel’s CEO looks to help ignite a new era of cancer treatments | PharmaVoice

Empowered Patient Podcast: Developing Immunotherapies Using Oncolytic Viruses to Change the Tumor Microenvironment

The Netherlands: ‘Boston by the North Sea?’

A glorious moment, knowing that we have secured the proceeds to deliver on our mission to develop better medicines for patients

We’re excited to join the @Nasdaq family! Now #NasdaqListed and trading: $CADL. Learn more about our IPO here:

Paul Peter Tak

© Paul Peter Tak.
All rights reserved.